Delcath Systems Announces First Patient Dosed in Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
Delcath Systems has dosed the first patient in its global Phase 2 DELUMA trial evaluating HEPZATO for liver-dominant metastatic breast cancer. The trial, initiated at the European Institute of Oncology in Milan, will enroll approximately 90 patients across more than 20 sites in the US and Europe.
Key figures
- Drug Name
- HEPZATO
- Phase Of Trial
- Phase 2
- Trial sites
- more than 20
- Trial enrollment target
- 90
- Us annual patient population
- 7000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.